MRK · Healthcare

Merck & Co., Inc.

Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: everything published this earnings window

News · 2026-11-07

• Product / Drug Pipeline ProgressImportance 31 · Surprise 42
  Merck reportedly initiated a global Phase 3 study of OHTUVAYRE in patients with COPD. The company was also set to present new HIV treatment and prevention data at a conference running November 8–11, 2026. The FDA set…
• Regulatory Approval MilestonesImportance 17 · Surprise 24
  The FDA set an April 22, 2027, target action date for two supplemental IDVYNSO applications. The reported date identifies the expected timing of the agency’s action on both applications. The digest does not quantify a…

News · 2026-11-06

• Litigation and Legal RiskImportance 41 · Surprise 48
  Halozyme’s third-quarter 2026 earnings call highlighted a patent dispute with Merck, and a separate report described the Merck litigation as ongoing. Halozyme reported SG&A expense of $58.2 million, up from $46.1…
• Melanoma Vaccine CollaborationImportance 34 · Surprise 42
  Moderna's personalized cancer vaccine, being developed with Merck, was cited as benefiting from positive Phase 3 melanoma trial results. The report connected those results to Moderna's stock performance but provided no…

News · 2026-11-05

• Keytruda SC LitigationImportance 47 · Surprise 60
  Third-party reporting says Halozyme secured legal victories against Merck in Europe over its Keytruda subcutaneous patent. The rulings prevent Merck from launching the product in key European markets. The report does…
• Revenue Performance and MixImportance 36 · Surprise 40
  Merck reported Q3 2026 sales of $18.09 billion, up 4.7% year over year, while net income fell 12.4% and diluted EPS declined 12.1%. Combined Keytruda and Keytruda Qlex sales rose 6% to $8.60 billion, including $830…
• Acquisition / Partnership / DivestitureImportance 31 · Surprise 42
  Merck announced acquisitions of Terns, Cidara, and TARGAN. It also licensed a KRAS G12D candidate. The digest provides no transaction values, payment terms, or additional strategic details for these deals.
• Market Demand TrendsImportance 31 · Surprise 32
  Merck’s two largest franchises, Keytruda and Gardasil, posted year-over-year sales growth in Q3 2026, although the article provides detailed demand commentary only for Keytruda. Combined Keytruda and Keytruda Qlex…

10-Q · 2026-11-04

• Acquisitions and DivestituresImportance 71 · Surprise 60
  Merck acquired Cidara in January 2026 for $9.2 billion and Terns in May 2026 for $6.8 billion, including payments to settle share-based awards of $570 million and $606 million, respectively. The acquisitions added…
• Competition and Market ShareImportance 63 · Surprise 64
  Generic competition drove significant declines in Januvia and Janumet sales after U.S. exclusivity ended in May 2026, and Janumet XR exclusivity ended in July; declines are expected to continue. Dificid sales fell 68%…
• Liquidity and Debt PositionImportance 60 · Surprise 74
  Cash and investments were $11.253 billion at September 30, 2026, down from $15.521 billion at December 31, 2025; working capital declined to $10.140 billion from $15.189 billion. Operating cash flow was $15.8 billion…
• WINREVAIR Demand GrowthImportance 59 · Surprise 64
  Winrevair sales rose 93% in the third quarter and 85% in the first nine months of 2026, largely reflecting higher demand and launch uptake in international markets. U.S. wholesaler and specialty pharmacy purchase…
• Vaccine Policy LitigationImportance 53 · Surprise 60
  In January 2026, the acting CDC director changed the U.S. child and adolescent immunization schedule, reducing routinely recommended vaccinations and introducing three recommendation categories. On March 16, 2026, a…
• Income Tax Rate ChangesImportance 52 · Surprise 42
  The effective tax rate was 8.9% in the third quarter of 2026, reflecting favorable discrete items and the jurisdictional mix of income and expense. For the first nine months of 2026, Merck recorded a $1.9 billion tax…
• Restructuring and Cost ReductionImportance 52 · Surprise 42
  Merck’s July 2025 restructuring program is expected to incur approximately $3.0 billion in cumulative pretax costs, about 60% cash, and generate approximately $1.7 billion in annual savings, substantially realized by…
• Research and Development ExpenseImportance 48 · Surprise 42
  Merck recorded a $5.7 billion research and development expense charge for the Terns asset acquisition in the first nine months of 2026, primarily for acquired in-process research and development with no alternative…
• Gross Margin DriversImportance 47 · Surprise 48
  Gross margin fell to 72.9% in the third quarter of 2026 from 77.7% in the third quarter of 2025, and to 73.6% in the first nine months of 2026 from 77.7% in the year-earlier period. Cost of sales increased 27% in the…
• Pricing and Market AccessImportance 46 · Surprise 42
  Merck reported that the government-set Medicare price for Januvia took effect on January 1, 2026, while negotiated prices for Janumet and Janumet XR are scheduled to take effect January 1, 2027. The company said the…
• German Health-Care ReformImportance 46 · Surprise 42
  Germany’s parliament approved the Statutory Health Insurance Contribution Rate Stabilization Act (GKV-BStabG) in July 2026. Most provisions take effect on January 1, 2027, and the company says the law will exert…
• MFN Drug Pricing AgreementImportance 46 · Surprise 42
  In December 2025, Merck entered a three-year agreement with the U.S. government addressing the administration’s most-favored-nation drug-pricing goals. Merck offers Januvia, Janumet and Janumet XR through a U.S.…
• IRS Tax DisputeImportance 46 · Surprise 42
  The IRS is examining Merck’s 2017 and 2018 tax returns, including the one-time transition tax enacted under the Tax Cuts and Jobs Act of 2017. In April 2025, Merck received Notices of Proposed Adjustment seeking…
• Revenue Performance and MixImportance 42 · Surprise 14
  Worldwide sales were $18.1 billion in the third quarter and $51.0 billion in the first nine months of 2026, up 5% in each period year over year; U.S. sales benefited from purchase timing by approximately $550 million…
• Keytruda SC LitigationImportance 42 · Surprise 48
  Preliminary injunctions prohibit continued Keytruda SC sales in Denmark and Italy and prevent launches in Germany, The Netherlands, Belgium, Ireland and France. Commercial availability in EU countries also depends on…
• Share Repurchase ProgramImportance 42 · Surprise 24
  Merck’s January 2025 authorization permits purchases of up to $10 billion of common stock and has no time limit. During the first nine months of 2026, the company repurchased $2.3 billion, or 19 million shares, under…
• Vaccine Market DemandImportance 41 · Surprise 48
  Gardasil and Gardasil 9 sales grew 14% in the third quarter, primarily on U.S. public-sector purchasing patterns and higher net pricing, but were up only 1% year to date as lower China and Japan demand offset growth in…
• LIPFENDRA Product LaunchImportance 41 · Surprise 60
  Merck announced FDA approval of Lipfendra tablets in July 2026 as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. Lipfendra is…
• Quarterly Dividend DeclarationImportance 41 · Surprise 14
  Merck paid $6.3 billion of dividends in the first nine months of 2026, compared with $6.2 billion in the same period of 2025. The board declared a quarterly dividend of $0.85 per share in May 2026 for the third…
• Trade Policy and TariffsImportance 40 · Surprise 42
  Merck reached an agreement with the U.S. Department of Commerce to delay Section 232 tariffs for three years. The delay enables the company to make U.S. investments to reshore manufacturing for American patients. The…
• Childhood Vaccine PolicyImportance 40 · Surprise 42
  In August 2026, the U.S. administration issued an executive order setting out proposed federal policy for “Gold Standard Childhood Vaccine Recommendations.” It recommends, among other measures, separate measles, mumps…
• Product / Drug Pipeline ProgressImportance 31 · Surprise 42
  Merck reported multiple late-stage candidates under regulatory review, including Lipfendra (MK-0616) in the EU, Japan, and China for hypercholesterolemia or dyslipidemia, and Idvynso (MK-8591A) in the EU and U.S. for…
• Operating Expense TrendsImportance 29 · Surprise 22
  SG&A expense increased 10% to $2.886 billion in the third quarter of 2026 and 8% to $8.491 billion in the first nine months, compared with the respective 2025 periods. Higher administrative costs and promotional…
• KEYTRUDA QLEX AdoptionImportance 26 · Surprise 24
  Keytruda Qlex is a subcutaneous pembrolizumab combination, and the filing reports U.S. and international demand growth for the combined Keytruda/Keytruda Qlex franchise. U.S. demand reflected greater utilization in…
• Animal Health DemandImportance 18 · Surprise 14
  Companion animal product sales grew 6% in the third quarter and 8% in the first nine months of 2026, driven largely by new product launches and partly offset by lower vaccine pricing. Bravecto sales were $264 million…
• Other Income (Expense), NetImportance 18 · Surprise 14
  Other expense, net, was $27 million in the third quarter of 2026, compared with $238 million of income in the third quarter of 2025. For the first nine months of 2026, the company reported $262 million of expense,…
• Manufacturing Network OptimizationImportance 17 · Surprise 24
  Merck plans to align the geography of its global manufacturing footprint with customers and changes in its business, while continuing to optimize its manufacturing network. Manufacturing actions under the 2025 program…

News · 2026-11-04

• Bravecto Product AuthorizationImportance 41 · Surprise 60
  Merck’s antiparasitic treatment Bravecto received emergency use authorization from the U.S. FDA for treating new screwworm infestations in dogs and puppies. The authorization expands Bravecto’s use beyond certain flea…
• Regulatory Approval MilestonesImportance null · Surprise null
  The U.S. Food and Drug Administration granted emergency use authorization for Merck’s Bravecto to treat new screwworm infestations in dogs and puppies. The authorization expands the U.S. use of Bravecto chewable…

News · 2026-11-03

• Revenue Performance and MixImportance 75 · Surprise 60
  A third-party report cited Merck’s third-quarter 2026 sales of US$18.1 billion. The report said Merck raised its full-year 2026 sales guidance to US$66.8 billion–US$67.3 billion. It also characterized pipeline…
• Guidance and OutlookImportance 75 · Surprise 60
  A third-party article reported that Merck raised its full-year 2026 sales guidance to $66.8 billion–$67.3 billion. Another article reported a mid-2030s revenue target of $70 billion. The digest does not provide further…
• Acquisition / Partnership / DivestitureImportance 40 · Surprise 42
  Lonza agreed to acquire Merck’s CDMO business, although the reported announcement did not disclose a transaction value. The divestiture is intended to sharpen the focus of Merck’s Life Science business sector. Merck’s…
• Acquisitions and DivestituresImportance 40 · Surprise 42
  Merck agreed to divest its contract development and manufacturing organization (CDMO) business to Lonza. The reported rationale is to sharpen the focus of Merck’s Life Science business sector and give the CDMO business…
• Product Launch and TransitionImportance 34 · Surprise 42
  Health Canada approved Merck Animal Health’s BRAVECTO® QUANTUM, a once-yearly injectable for treating and preventing flea and tick infestations in dogs and puppies aged six months and older. It provides up to 12 months…
• Product / Drug Pipeline ProgressImportance 34 · Surprise 42
  Merck Animal Health received a positive opinion from the European Medicines Agency’s Committee for Veterinary Medicinal Products for NUMELVI™ (atinvicitinib) tablets for dogs. If approved by the European Commission,…
• Clinical Pipeline DevelopmentsImportance 34 · Surprise 42
  Merck initiated ENHANCE-3, a Phase 3 trial evaluating OHTUVAYRE® (ensifentrine) to prevent COPD exacerbations in adults receiving standard of care who have a history of exacerbations. Recruitment has begun, with the…

News · 2026-11-02

• Revenue Performance and MixImportance 57 · Surprise 64
  Merck reported approximately $18.1 billion in total revenue, including $8.6 billion from the Keytruda franchise. Winrevair sales were $694 million, up 93%, and represented roughly 3.8% of total revenue. Winrevair grew…
• WINREVAIR Demand GrowthImportance 57 · Surprise 64
  Merck’s WINREVAIR sales reached $694 million, up 93% year over year, according to the October 29 release cited in the report. The article describes the medicine as fast-growing but says it represented roughly 3.8% of…
• Keytruda Patent Expiration OutlookImportance 50 · Surprise 24
  The report says Keytruda faces U.S. patent losses starting in 2028. Merck’s personalized cancer-vaccine collaboration with Moderna is presented as a potential response to that patent cliff. Overall-survival data and…
• Guidance and OutlookImportance 47 · Surprise 60
  Merck raised its 2026 earnings outlook after reporting third-quarter results. The report attributes the outlook increase to the company’s strong third-quarter performance. It provides no revised guidance amount or range.
• Oncology Pipeline ProgressImportance 39 · Surprise 42
  Moderna’s personalized mRNA cancer vaccine intismeran, developed with Merck, is being tested in combination with Keytruda. The report says the combination significantly reduced the risk of recurrence or death in…
• Regulatory Approval MilestonesImportance 31 · Surprise 42
  The FDA accepted two supplemental New Drug Applications for Merck’s oral HIV medicine IDVYNSO. The applications are under review. An FDA action date is set for 2027.
• HIV Pipeline ProgressImportance 28 · Surprise 24
  Merck plans to present data at HIV Drug Therapy Glasgow 2026 on daily and investigational once-weekly oral HIV treatments and investigational once-monthly oral pre-exposure prophylaxis. The data include Phase 3…

News · 2026-11-01

• Quarterly Earnings PerformanceImportance 33 · Surprise 6
  Third-party reports said Merck generated quarterly revenue of $18.09 billion, exceeding analyst estimates. The reports gave adjusted earnings per share of $2.49 for the quarter. Both figures were described as stronger…

News · 2026-10-31

• Melanoma Vaccine CollaborationImportance 61 · Surprise 92
  In the Phase 3 INTerpath-001 trial in resected high-risk melanoma, Merck’s KEYTRUDA combined with Moderna’s personalized mRNA therapy intismeran autogene reduced the risk of recurrence or death by 42% versus KEYTRUDA…
• Guidance / OutlookImportance 45 · Surprise 6
  Merck expects full-year 2026 revenue to be around $67.05 billion. The reported estimate was described as close to analysts’ expectations.
• Guidance and OutlookImportance 45 · Surprise 6
  Merck expects full-year 2026 revenue of around $67.05 billion. The reported outlook was described as close to analysts’ estimates. The digest provides no further revenue, margin, or capital-expenditure guidance in this…
• Revenue Performance and MixImportance 25 · Surprise 14
  Merck reported Q3 2026 revenue of $18.09 billion, up 4.7% year over year. Keytruda and other product growth drove the results, according to the reporting. A separate earnings recap put quarterly revenue at about $18.1…

News · 2026-10-30

• Guidance and OutlookImportance 40 · Surprise 42
  Management raised Merck’s full-year 2026 sales and earnings outlook, but the report does not provide the revised forecast amounts. Executives cited generic competition and vaccine-market pressures as factors that could…
• Quarterly Earnings PerformanceImportance 31 · Surprise 14
  Merck reported third-quarter 2026 non-GAAP earnings of $2.49 per share, 17.5% above the Zacks consensus estimate of $2.12. Earnings per share declined 3.5% year over year from $2.58. Revenue rose 4.7% year over year to…
• Competition and Pricing PressureImportance 26 · Surprise 24
  Executives cautioned that generic competition and vaccine market pressures could temper Merck’s growth in 2027. The report did not identify specific generic competitors, products facing pressure, or quantified market…
• Market Demand TrendsImportance 20 · Surprise 24
  Merck was reported to have strong oncology demand in the third quarter of 2026. The report also cited expanding contributions from newer medicines, without naming the products or quantifying demand or sales…